Department of Neurology (Division of Behavioral Neurology), Mayo Clinic, Rochester, MN, USA,
J Neurol. 2014 Mar;261(3):604-14. doi: 10.1007/s00415-014-7243-9. Epub 2014 Jan 22.
The logopenic variant of primary progressive aphasia (lvPPA) strongly associates with Alzheimer's disease, but can also associate with frontotemporal lobar degeneration. We aimed to assess the frequency of lvPPA in patients with speech and language disorders without β-amyloid deposition, and to perform detailed neuroimaging and genetic testing in such lvPPA patients. Seventy-six patients with a neurodegenerative speech and language disorder and Pittsburgh compound B (PiB) PET imaging demonstrating no β-amyloid deposition were analyzed. Six lvPPA patients (8 %) were identified. All six underwent progranulin (GRN) gene testing. Structural abnormality index maps and Cortex ID analysis were utilized to assess individual patterns of grey matter atrophy on MRI and hypometabolism on 18-F fluorodeoxyglucose (FDG) PET. Statistical parametric mapping was used to perform MRI and FDG-PET group comparisons between those with (GRN-positive) and without (GRN-negative) progranulin mutations. All six lvPPA patients showed left temporoparietal atrophy and hypometabolism. Three patients (50 %) were GRN-positive. Speech, language, and neurological and neuropsychological profiles did not differ between GRN-positive and negative patients, although GRN-positive patients had family histories, were on average 8 years younger, and had lower PiB-PET ratios. All six patients showed similar patterns of atrophy and hypometabolism, although, as a group, GRN-positive patients had more severe abnormalities, particularly in anteromedial temporal lobes. Logopenic PPA accounts for a small minority of neurodegenerative speech and language disorders not associated with β-amyloid deposition. Identification of such patients, however, should prompt testing for GRN mutations, since GRN-positive patients do not have distinctive features, yet account for 50 % of this patient population.
语言流畅性变异型原发性进行性失语(lvPPA)与阿尔茨海默病强烈相关,但也可能与额颞叶变性相关。我们旨在评估无β-淀粉样蛋白沉积的言语和语言障碍患者中 lvPPA 的频率,并对这些 lvPPA 患者进行详细的神经影像学和基因检测。分析了 76 名患有神经退行性言语和语言障碍且匹兹堡化合物 B(PiB)PET 成像显示无β-淀粉样蛋白沉积的患者。确定了 6 名 lvPPA 患者(8%)。所有 6 名患者均进行了颗粒蛋白前体(GRN)基因检测。利用结构异常指数图和皮质 ID 分析来评估 MRI 上灰质萎缩和 18-F 氟脱氧葡萄糖(FDG)PET 上代谢减退的个体模式。使用统计参数映射对具有(GRN 阳性)和不具有(GRN 阴性)颗粒蛋白前体突变的患者进行 MRI 和 FDG-PET 组比较。所有 6 名 lvPPA 患者均表现出左颞顶叶萎缩和代谢减退。3 名患者(50%)GRN 阳性。GRN 阳性和阴性患者的言语、语言、神经和神经心理学特征没有差异,尽管 GRN 阳性患者有家族史,平均年轻 8 岁,PiB-PET 比值较低。所有 6 名患者均表现出相似的萎缩和代谢减退模式,尽管作为一个组,GRN 阳性患者的异常更为严重,特别是在前内侧颞叶。无β-淀粉样蛋白沉积的神经退行性言语和语言障碍中,语言流畅性变异型原发性进行性失语仅占一小部分。然而,此类患者的识别应促使进行 GRN 突变检测,因为 GRN 阳性患者没有独特的特征,但占该患者人群的 50%。